Ind-Swift Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Ind-Swift Limited with three other
companies in this sector in India:
Lasa Supergenerics Ltd
sales of 2.44 billion Indian Rupees [US$33.10 million]
Mangalam Drugs & Organics Limited
(2.79 billion Indian Rupees [US$37.97 million]
Gufic Biosciences Ltd
(3.01 billion Indian Rupees [US$40.90 million]
of which 95%
Ind-Swift Limited reported sales of 2.71 billion Indian Rupees (US$36.77 million)
March of 2018.
a very small
increase of 1.3%
versus 2017, when the company's sales were 2.67 billion Indian Rupees.
Despite this increase, sales are still
below the level achieved in 2016, when Ind-Swift Limited
reported sales of 3.04 billion Indian Rupees.